Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hualan influenza mRNA vaccine
- Development stage
- Unknown
- Lead developer
- Hualan Biological Vaccine
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Hualan influenza mRNA vaccine is an investigational messenger RNA (mRNA)-based vaccine developed by Hualan Biological Vaccine for the prevention of influenza. The vaccine utilizes mRNA technology to deliver genetic instructions encoding influenza virus-related antigens, such as hemagglutinin. Upon administration, host cells express these antigens, triggering a robust humoral and cellular immune response against the targeted influenza strains. This platform offers advantages over traditional egg-based or cell-based manufacturing, including flexible antigen design and shorter production cycles, which allow for rapid updates in response to seasonal antigenic drift. In September 2026, the vaccine received clinical trial approval (IND) from China's National Medical Products Administration (NMPA), making it the first domestic influenza mRNA vaccine cleared for clinical trials in China.
- Other names
- novel influenza virus mRNA vaccine新型流感病毒mRNA疫苗
Beyond the preview
Go deeper on Hualan influenza mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hualan influenza mRNA vaccine.